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Introduction
The renin angiotensin system (RAS) is involved in regulating blood pressure and fluid and electrolyte homeostasis (Kobori et al., 2007) . In the RAS, angiotensinogen (AGT) is metabolized into angiotensin (Ang) I and Ang I is then converted to Ang II by angiotensin converting enzyme (ACE) (Campbell, 2014; Paul et al., 2006) . The evidence indicates that Ang II, a main bioactive component of the RAS, affects a wide range of central and peripheral components of the sensory systems (Burkhalter et al., 2001; Pelegrini-da-Silva et al., 2005; Wu et al., 2000) , and is mediated by Ang II type 1 (AT1) and Ang II type 2 (AT2) receptors.
Traditionally, Ang II has been considered to be generated by the circulating RAS, but additional local organ-specific RAS have been confirmed to exist in several organs (Bader, 2010) . In both rat and human dorsal root ganglia (DRG) Ang II is co-localized in two known regulators for nociception and sensory transmission: substance P and calcitonin gene-related peptide (Patil et al., 2010) . We have previously demonstrated that when mice are administered intrathecal (i.t.) Ang II, p38 mitogen-activated protein kinase (MAPK) is phosphorylated through AT1 receptors, leading to nociceptive behavior (Nemoto et al., 2013 (Nemoto et al., , 2015a . Moreover, injections of 2% formalin into mice hind paws increases Ang II approximately 1.5-fold on the ipsilateral side of the lumbar superficial dorsal horn, and AT1 receptor antagonist losartan dose-dependently produces an antinociceptive effect by This article has not been copyedited and formatted. The final version may differ from this version.
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6 inhibiting p38 MAPK phosphorylation (Nemoto et al., 2015b) . Taken together, Ang II may act as a neurotransmitter and/or neuromodulator as nociceptive information is transmitted through the spine.
Neuropathy occurs in about 50% of patients with diabetes (Dyck et al., 1993; Veves et al., 2008) as a diffuse symmetric injury to peripheral nerves, and has major implications on the quality of life and public health costs (Boulton et al., 2005; Gordois et al., 2003) . One of the prominent pathognomonic symptoms of diabetic neuropathy is neuropathic pain, which affects 16% of diabetics but is frequently unreported (12.5%) and often inadequately treated (39%) (Daousi et al., 2004) . The pathogenesis of diabetic neuropathic pain is complex and thus remains poorly understood.
In the diabetic state, there is an increase in plasma ACE activity and levels of Ang II (van Dijk et al., 2001; Van Dyk et al., 1994) and there have been many studies conducted on the relationship between RAS and diabetic complications. One of the outcomes of RAS activation is the hypertrophy of various renal cells promoted by Ang II, which leads to the development of diabetic nephropathy (Leehey et al., 2000; Vidotti et al., 2004) . Evidence obtained from both animal and clinical studies supports the hypothesis that nephropathy can be effectively treated by intrarenal RAS blockade (Hollenberg et al., 2003) . In addition, the retinal RAS is also activated in diabetic mice and treatment with AT1 receptor antagonists This article has not been copyedited and formatted. The final version may differ from this version.
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7 significantly ameliorates the course of retinopathy (Ebrahimian et al., 2005) . Although the role of spinal RAS on diabetic neuropathic pain has not been studied to date, these reports suggest that RAS is also activated in the spinal cord and involved in diabetic neuropathic pain.
Thus, in the present study we examined whether the spinal RAS is responsible for diabetic neuropathic pain using the streptozotocin (STZ)-induced diabetic mouse model. This article has not been copyedited and formatted. The final version may differ from this version. Induction of diabetes. STZ (Sigma Aldrich, St Louis, MI) was dissolved in 0.1 N citrate buffer (pH 4.5), and a single intravenous (i.v.) injection was given to mice promptly thereafter to induce diabetes (Kamei et al., 1991) . Control mice were injected with vehicle alone. Blood samples from the tail vein were taken to measure blood glucose levels via the FreeStyle Optium Blood Glucose Monitoring System (Abbott Japan Co. Ltd., Osaka, Japan).
Intrathecal injections.
Intrathecal (i.t.) injections were performed as previously described (Nemoto et al., 2013 (Nemoto et al., , 2014 (Nemoto et al., , 2015a (Nemoto et al., , 2015b . This article has not been copyedited and formatted. The final version may differ from this version. On the other hand, if a negative response occurred, the next strongest force was applied. The mean left and right paw scores of trials for each mouse were calculated.
Stimulation of equal intensity (0.4 g filament) was applied to the plantar surface of the left and right hind paws and repeated 10 times at intervals of 5 s to assess the dose-dependent effect of losartan on tactile allodynia. The frequency of sharp withdrawal responses was measured. Immunohistochemical study. MapAnalyzer: Immunhistochemical staining was conducted as previously described (Nakagawasai et al., 2003; Nemoto et al., 2013 Nemoto et al., , 2014 Nemoto et al., , 2015b Confocal microscopy: Immunohistochemical staining was conducted as previously described (Nemoto et al., 2014 (Nemoto et al., , 2015a Western blotting. Western blotting was conducted as previously described (Nemoto et al., 2013 (Nemoto et al., , 2014 (Nemoto et al., , 2015a . Electrophoresis was performed in 7.5% acrylamide gels for the detection of ACE; 10% acrylamide gels were used in all other cases. Proteins were transferred electrically from the gel onto a polyvinylidene difluoride membrane using a semi-dry blotting This article has not been copyedited and formatted. The final version may differ from this version. 
Drugs and antibodies.
RT-PCR.
Total RNA was isolated from the spinal cord, kidney, and liver of non-treated mice using TRI Reagent according to the manufacturer's protocol. Total RNA was reverse-transcribed using ReverTraAce and oligo (dT) primers. PCR was conducted using the containing Go Taq qPCR Master mix (10 μL), RT template (2 μL), water (7 μL), and primers
(1 μL) using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA).
The amount of each PCR product was normalized to GAPDH.
Statistical methods. Data are expressed as means ± SEM. Significant differences were analyzed by one-way or two-way analysis of variance (ANOVA), followed by Fisher's This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. and 20 mg/kg, while the withdrawal threshold was significantly decreased on day 1 only, and on days 1-3 after injection, respectively (Fig. 1C) . Therefore, to exclude the possibility that STZ has a direct action on neurons, we used mice on day 14 post-injection at 200 mg/kg, which was a point in time that showed a marked decrease in pain threshold.
Effects of Ang II receptor antagonists on STZ-induced tactile allodynia. To investigate whether spinal Ang II receptors are involved in STZ-induced tactile allodynia, the effects of i.t. administration of losartan or PD13319, which are AT1 and AT2 receptor antagonists, respectively, were examined on day 14 after STZ injection. Tactile allodynia was measured before (pre) and after (15, 30, 60, 90 and 120 min) i.t. injection. In vehicle-treated mice, losartan did not affect the withdrawal threshold at any time throughout the experimental period (Fig 2A) . Similarly, PD123319 showed no significant effects (Fig. 2B ). On the other hand, tactile allodynia was significantly inhibited 60-120 min after i.t. administration of losartan (30 nmol) in STZ mice compared to Ringer-treated controls (Fig. 2C ). In contrast, PD123319 (30 nmol) did not have any significant effects on STZ-induced tactile allodynia (Fig. 2D ), although it has been shown to significantly reduce the pressor effect induced by i.t.
administration of Ang II at a lower dose of 13.6 nmol (Park and Henry, 1997).
We additionally examined the dose-dependency of losartan (10-30 nmol) on STZ-induced tactile allodynia 90 min after administration. As shown in Fig. 2E , losartan
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3B where lowest concentration is black and highest is white). Relatively high fluorescence intensities for Ang II were seen in the lumbar superficial dorsal horn (laminae I and II) in vehicle mice (Fig. 3B) . Importantly, these intensities increased by approximately 3-fold in STZ mice, indicating a potential increase in local RAS activity (Fig. 3C) .
Phosphorylation of p38 MAPK in the lumbar spinal cord of STZ mice. To investigate whether spinal p38 MAPK is activated in STZ mice, we examined the phosphorylation of p38 MAPK in the lumbar dorsal cord by Western blotting. There was a marked increase in the phosphorylation of p38 MAPK in STZ mice (Fig. 4A) . However, i.t.
administration of losartan (30 nmol) had a significant preventative effect on this increase ( 4A). High fluorescence intensity for phospho-p38 MAPK was seen in the lumbar superficial dorsal horn of Ringer-injected STZ mice (Fig.4B) . Furthermore, the intensity was increased approximately 1.5-fold in Ringer-injected STZ mice compared to Ringer-injected vehicle mice, and was significantly attenuated by losartan (Fig. 4C) . (Fig. 6A, B) . In contrast, the mRNA levels for AT1A receptor and cathepsin D did not differ significantly between STZ and vehicle mice (Fig. 6C, D) .
Levels of ACE, AT1 receptors and AGT in the lumbar spinal cord of STZ mice.
This article has not been copyedited and formatted. The final version may differ from this version. 
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We determined the levels of ACE, AT1 receptors, and AGT in the lumbar dorsal spinal cord of STZ mice by Western blotting. Spinal ACE increased significantly in STZ mice compared to vehicle mice ( Fig. 7A and B) . On the other hand, the levels of AGT and AT1 receptors did not significantly differ between STZ and vehicle mice (Fig. 7A, C and D) . Moreover, to quantify the levels of these RAS components in the superficial dorsal horn, we performed immunohistochemical labeling and measured the intensity of fluorescence in laminae I and II (Fig. 7H) . However, the intensities of AT1 receptors (Fig. 7I) and AGT (Fig. 7J ) in diabetic mice did not differ from those of vehicle mice.
Dual immunolabeling of ACE and cell-specific markers in the mouse lumbar superficial dorsal horn. Dual immunofluorescence staining for ACE was performed in conjunction with that for cell-specific markers-NeuN for neurons, GFAP for astrocytes, and
Iba-1 for microglia-to determine the cell types that are involved in the production of Ang II.
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ACE was localized in NeuN-immunoreactive (IR) cells (Fig. 8 A-C) , while it was absent in GFAP-and Iba-1-IR cells (Fig. 8 D-I ). These results indicated that ACE is expressed in neurons, but not in astrocytes or microglial cells in the mouse superficial dorsal horn.
Discussion
We have previously reported that Ang II may act as a neurotransmitter and/or neuromodulator in the spinal transmission of nociceptive information (Nemoto et al., 2013 (Nemoto et al., , 2015a (Nemoto et al., , 2015b . 23 can cause structural and functional changes in the nerves, and possibly neuropathic pain (Boulton, 1992; Tesfaye et al., 1996) . Moreover, the development of STZ-induced diabetic neuropathic pain is prevented by pretreatment with insulin (Aley and Levine, 2001;
Messinger et al., 2009). These previous reports suggest that STZ-induced diabetic neuropathic pain may be frequently associated with hyperglycemia. In our study, lower doses of STZ (2 and 20 mg/kg) had no effect on blood glucose levels, while the withdrawal threshold was only briefly decreased to a significant level (on days 1-3) following injection. To exclude the possibility that STZ has a direct action on neurons, as reported previously (Pabbidi et al.,
2008), we used STZ (200 mg/kg)-injected mice with altered blood glucose levels from a later time point (day 14), as our model for diabetes-induced neuropathic pain.
Oral administration of an Ang II receptor antagonist or ACE inhibitor increases motor nerve conduction velocity, and is decreased in STZ rats without affecting blood glucose levels (Coppey et al., 2006) . This suggests that blocking the activation of the RAS provides an effective approach toward the prevention/reversal of diabetes-induced neuronal dysfunction.
In addition, it has been shown that oral administration of telmisartan, an AT1 receptor antagonist has the potential to attenuate neuropathic pain in a chronic constriction injury It has been reported that renin gene expression and AT1 receptor protein synthesis are increased, while the expression levels of AGT and ACE mRNAs remain unchanged, in the proximal tubules of STZ rats (Zimpelmann et al., 2000) . On the other hand, an increase in AGT mRNA leading to the up-regulation of Ang II has been observed in the retinas of STZ mice (Ebrahimian et al., 2005) . These reports indicate that several local Ang II-generating system components are increased in diabetes depending on the organ or tissue under investigation. In this study, the expression of both AGT and ACE genes were increased in the lumbar dorsal spinal cord of STZ mice, whereas there was no change in cathepsin D expression. However, at the protein level, only ACE was increased in a significant manner while AGT was not changed. Moreover, we observed that spinal ACE is present in neurons but absent from glial cells in the superficial dorsal spinal cord. Therefore, the present results suggest that, only the expression of ACE was increased and among the local Ang II-generating system components in the spinal cord of the STZ mice, it was responsible for the increase in Ang II levels.
Regarding the expression of AT1 receptors, only transcripts for AT1A but not AT1B subtypes were expressed in the mouse lumbar dorsal spinal cord. Most species express a This article has not been copyedited and formatted. The final version may differ from this version. (Zeng et al., 2003) . In the STZ mouse model, the local expression levels of AT1A receptor mRNA and AT1 receptors may not be influenced by the increase in Ang II in the spinal cord.
In conclusion, our data show that a local Ang II-generating system is present in the spinal cord. Among local components, the expression of ACE was increased in STZ-induced diabetic mice, which led to an increase in Ang II levels. Moreover, this increase in Ang II 
